CCL18

Source: Wikipedia, the free encyclopedia.
CCL18
Available structures
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_002988

n/a

RefSeq (protein)

NP_002979

n/a

Location (UCSC)Chr 17: 36.06 – 36.07 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Chemokine (C-C motif) ligand 18 (CCL18) is a small

rodents
that can be studied. The receptor for CCL18 has been identified in humans only recently, which will help scientists understand the molecule's role in the body.

CCL18 is produced and secreted mainly by innate immune system, and has effects mainly on the adaptive immune system. It was previously known as Pulmonary and activation-regulated chemokine (PARC), dendritic cell (DC)-chemokine 1 (DC-CK1), alternative macrophage activation-associated CC chemokine-1 (AMAC-1), and macrophage inflammatory protein-4 (MIP-4).

Gene and protein structure

The gene of CCL18 is most similar to

mutations.[4][5] CCL18 is an 89 amino-acid-long protein, with a 20 amino-acid-long peptide signalling sequence (to signal its secretion) at the N’ terminus which is cleaved in the endoplasmic reticulum into a 69 amino-acid-long mature protein.[3]

The gene structure of CCL18[6]

Sources

CCL18 is produced mainly by

IFN-gamma, a T-helper 1 type response cytokine important for cell-mediated immunity, dampens the production of CCL18.[10] Furthermore, CCL18 is induced by fibroblasts, specifically by induction of collagen produced by fibroblasts, which is important in tissue healing and repair.[9]
Finally, CCL18 is constitutively and highly expressed in the lungs, suggesting that CCL18 plays role in maintaining homeostasis.

Chemotactic functions

FoxP3 as most T-regulatory cells do, and instead non-antigen specifically exert their immunosuppressive functions by secreting IL-10.[9]
It is thought that these recruited cells maintain homeostasis under healthy conditions.

Receptor

The classical receptors for chemokines are

pathologies
would allow for better understanding of CCL18's function in these diseases.

Effector functions

CCL18 has a plethora of functions that have been characterized in vitro and in vivo. Strangely, CCL18 seems to play a part in both activation of the immune system and the induction of tolerance and homeostasis at steady-state conditions.


Immune activation

The production of CCL18 is induced by T-helper 2 type cytokines, namely IL-4 and IL-13. Coupled with the fact that CCL18 is highly expressed in patients with allergic asthma[18] and other hypersensitivity diseases,[6] CCL18 seems to play an important role for generating and maintaining a T-helper 2 (Th2) type response. Furthermore, the addition of CCL18 as an adjuvant for a malaria vaccine have shown efficacy, perhaps by recruiting immune cells to the site of vaccination.[19] Finally, CCL18 is expressed by dendritic cells in the germinal center of inflamed lymph nodes, and recruits naïve B-cells for antigen presentation.[20] Perhaps aberrant CCL18 expression is involved in the generation of chronic Th2 response, leading to asthma or arthritis.

Immunosuppression

In addition to immune-activating effects, CCL18 also has strong immunosuppressive effects. CCL18 induces immature dendritic cells to differentiate into an immunosuppressive dendritic cell that is capable producing CCL18 which attract T-cells, suppressing effector T-cell function, and generating T-regulatory cells by secreting large amounts of IL-10.[10][21] Furthermore, exposure to CCL18 by macrophages causes them to mature in the #M2 spectrum, which promotes immunosuppression and healing.[9]

Involvement in disease

Aberrant CCL18 expression is observed in many diseases, and it is thought that these abnormal expression patterns play a key role in these diseases.[6] This table shows a list of all the diseases that CCL18 is involved in.

Breast cancer

The most understood disease that CCL18 is involved in is in breast cancer, where CCL18 induces metastasis of breast cancer cells by binding to PITPNM3.[15] Perhaps CCL18, in breast cancers, is acting as an immunosuppressive cytokine by generating T-regulatory cells, generating immunosuppressive dendritic cells and macrophages, and recruiting effector T-cells to these dendritic cells and macrophages to abolish their anti-cancer functions and allowing the cancer to escape the immune system.

Autoimmunity and hypersensitivity

CCL18 is highly expressed in T-helper 2 mediated

autoimmune diseases, such as asthma and arthritis.[13] CCL18 is expressed at much higher levels in allergic patients compared to healthy patients and respond aggressively to innocuous antigens.[13] Allergic patients also had higher amounts of activated T-cells in the lungs, suggesting that CCL18 recruitment of these cells is contributing to hypersensitivity. In addition to lung hypersensitivities, these patterns were also observed in dermatitis patients.[6] Furthermore, a similar pattern was also observed in arthritis patients, where CCL18 was expressed at much higher rates by dendritic cells in affected patients.[22]
However, in arthritis, perhaps the increased CCL18 is an attempt to suppress effector T-helper 1 cells that are self-reactive.

References

  1. ^ a b c ENSG00000278167, ENSG00000278006 GRCh38: Ensembl release 89: ENSG00000275385, ENSG00000278167, ENSG00000278006Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^
    S2CID 6071325
    .
  4. ^ .
  5. .
  6. ^ .
  7. ^ .
  8. .
  9. ^ .
  10. ^ .
  11. .
  12. .
  13. ^ .
  14. .
  15. ^ .
  16. .
  17. ^ .
  18. .
  19. .
  20. .
  21. .
  22. .

External links

This page is based on the copyrighted Wikipedia article: CCL18. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy